Eustratios Bananis

3.1k total citations · 3 hit papers
60 papers, 2.2k citations indexed

About

Eustratios Bananis is a scholar working on Rheumatology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Eustratios Bananis has authored 60 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Rheumatology, 21 papers in Pulmonary and Respiratory Medicine and 16 papers in Genetics. Recurrent topics in Eustratios Bananis's work include Rheumatoid Arthritis Research and Therapies (27 papers), Advanced Breast Cancer Therapies (21 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Eustratios Bananis is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (27 papers), Advanced Breast Cancer Therapies (21 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Eustratios Bananis collaborates with scholars based in United States, Germany and Canada. Eustratios Bananis's co-authors include Allan W. Wolkoff, John W. Murray, Roy Fleischmann, Richard J. Stockert, Joanne Fuiman, Majed Khraishi, Philip J. Mease, Daniel Alvarez, Dafna D. Gladman and Peter Satir and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Cell Biology and Cancer Research.

In The Last Decade

Eustratios Bananis

58 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

2022 114 citations Massimo Cristofanilli, Hope S. Rugo et al. Clinical Cancer Research profile →
Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.

2022 109 citations Richard S. Finn, Hope S. Rugo et al. profile →
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

2024 81 citations Dennis J. Slamon, Véronique Dièras et al. profile →

Peers

Countries citing papers authored by Eustratios Bananis

Since Specialization

Citations

This map shows the geographic impact of Eustratios Bananis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eustratios Bananis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eustratios Bananis more than expected).

Fields of papers citing papers by Eustratios Bananis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eustratios Bananis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eustratios Bananis. The network helps show where Eustratios Bananis may publish in the future.

Co-authorship network of co-authors of Eustratios Bananis

This figure shows the co-authorship network connecting the top 25 collaborators of Eustratios Bananis. A scholar is included among the top collaborators of Eustratios Bananis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eustratios Bananis. Eustratios Bananis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program 2025 ·Inflammatory Bowel Diseases ·Bruce E. Sands, Marla C. Dubinsky, Paulo Gustavo Kotze, Séverine Vermeire, Remo Panaccione, Millie D. Long, John Woolcott, Joseph Wu, Aoibhinn McDonnell, Martina Goetsch, Eustratios Bananis, Andrés Yarur	0
2	P705 Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programme 2024 ·Journal of Crohn s and Colitis ·Gary R. Lichtenstein, Jessica R. Allegretti, Edward V. Loftus, Peter M. Irving, Rupa Banerjee, (unknown), Tanja Kuehbacher, Eustratios Bananis, John Woolcott, (unknown), (unknown), Michael J. Keating, (unknown), Silvio Danese	0
3	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study breakdown → 2022 ·Clinical Cancer Research ·Massimo Cristofanilli, Hope S. Rugo, Seock‐Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O’Leary, Fabrice André, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner	114
4	Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3 2022 ·The Breast ·Hope S. Rugo, Seock‐Ah Im, Anil A. Joy, Yaroslav Shparyk, Janice M. Walshe, Bethany Sleckman, Sherene Loi, Kathy Puyana Theall, Sindy Kim, Xin Huang, Eustratios Bananis, Reshma Mahtani, Richard S. Finn, Véronique Dièras	3
5	Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer 2021 ·Journal of Breast Cancer ·Jee Hyun Kim, Seock‐Ah Im, Sung Hoon Sim, Eustratios Bananis, Xin Huang, (unknown), Sung‐Bae Kim	3
6	Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up 2021 ·The Oncologist ·Richard S. Finn, Hope S. Rugo, Karen A. Gelmon, Massimo Cristofanilli, Marco Colleoni, Sherene Loi, Patrick Schnell, Dongrui R. Lu, Kathy Puyana Theall, A. Mori, Eric Gauthier, Eustratios Bananis, Nicholas C. Turner, Véronique Dièras	40
7	Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3 2021 ·The Oncologist ·Hope S. Rugo, Massimo Cristofanilli, Sybille Loibl, Nadia Harbeck, Angela DeMichele, Hiroji Iwata, (unknown), Adam Brufsky, Kathy Puyana Theall, Xin Huang, Lynn McRoy, Eustratios Bananis, Nicholas C. Turner	21
8	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) 2020 ·Breast Cancer Research and Treatment ·Richard S. Finn, Katalin Boér, Igor Bondarenko, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, Олександр Войтко, Eustratios Bananis, Lynn McRoy, Keith D. Wilner, Xin Huang, Sindy Kim, Dennis J. Slamon, Johannes Ettl	111
9	Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2 2019 ·Clinical Breast Cancer ·Hope S. Rugo, Richard S. Finn, Karen A. Gelmon, Anil A. Joy, Nadia Harbeck, Aurelio Castrellon, Hirofumi Mukai, Janice M. Walshe, A. Mori, Eric Gauthier, Dongrui R. Lu, Eustratios Bananis, Miguel Martín, Véronique Dièras	24
10	A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population 2018 ·Seminars in Arthritis and Rheumatism ·Alan Kivitz, Stanley Cohen, Edward Keystone, Ronald van Vollenhoven, Boulos Haraoui, Jeffrey Kaine, Haiyun Fan, Carol A. Connell, Eustratios Bananis, Liza Takiya, Roy Fleischmann	33
11	Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses 2018 ·Rheumatology and Therapy ·Vibeke Strand, Arthur Kavanaugh, Alan Kivitz, Désirée van der Heijde, Kenneth Kwok, Ermeg L. Akylbekova, (unknown), (unknown), Carol A. Connell, Eustratios Bananis, Josef S Smolen	9
12	Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials 2015 ·The Journal of Rheumatology ·Xenofon Baraliakos, Andrew Koenig, Heather Jones, Annette Szumski, David H. Collier, Eustratios Bananis	35
13	Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs 2015 ·Annals of the Rheumatic Diseases ·Christina Charles‐Schoeman, Gerd R Burmester, Peter Nash, Cristiano A. F. Zerbini, Koshika Soma, Kenneth Kwok, Thijs Hendrikx, Eustratios Bananis, Roy Fleischmann	59
14	Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis 2014 ·Lara D. Veeken ·Roy Fleischmann, Andrew Koenig, Annette Szumski, Henk Nab, Lisa Marshall, Eustratios Bananis	13
15	Impact of etanercept-methotrexate therapy on patient-reported outcomes in moderately active rheumatoid arthritis: Australian results from the induction period of preserve trial 2012 ·Internal Medicine Journal ·Peter Nash, (unknown), Paul Bird, Eustratios Bananis, (unknown), Annette Szumski, Heather Jones, (unknown), (unknown), Krishan Thirunavukkarasu	1
16	Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study 2012 ·Annals of the Rheumatic Diseases ·Paul Emery, Tore K Kvien, Bernard Combe, Bruce Freundlich, Deborah Robertson, Tahmina Ferdousi, Eustratios Bananis, Ronald Pedersen, Andrew Koenig	62
17	PMS18 Impact of Etanercept-Methotrexate Therapy on Patient-Reported Outcomes in Moderately Active Rheumatoid Arthritis (RA) Patients of Europe, Latin America, and Asia 2012 ·Value in Health ·Zoltán Szekanecz, Jeng‐Hsien Yen, Pedro C. Miranda, Annette Szumski, Eustratios Bananis, (unknown), (unknown), (unknown)	2
18	When is switching warranted among biologic therapies in rheumatoid arthritis? 2012 ·Expert Review of Pharmacoeconomics & Outcomes Research ·Alan Reynolds, Andrew Koenig, Eustratios Bananis, Amitabh Singh	30
19	Kif5B and Kifc1 Interact and Are Required for Motility and Fission of Early Endocytic Vesicles in Mouse Liver 2007 ·Molecular Biology of the Cell ·Sangeeta Nath, Eustratios Bananis, Souvik Sarkar, Richard J. Stockert, Ann O. Sperry, John W. Murray, Allan W. Wolkoff	55
20	Immunofluorescence Microchamber Technique for Characterizing Isolated Organelles 2002 ·Analytical Biochemistry ·John W. Murray, Eustratios Bananis, Allan W. Wolkoff	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact